292 related articles for article (PubMed ID: 24026795)
1. Acute generalised exanthematous pustulosis induced by Pneumocystis jirovecii pneumonia prophylaxis with dapsone.
Vas A; Laws P; Marsland A; McQuillan O
Int J STD AIDS; 2013 Sep; 24(9):745-7. PubMed ID: 24026795
[TBL] [Abstract][Full Text] [Related]
2. Adverse reactions associated with dapsone therapy in HIV-positive patients: a case presentation and review.
Stroup JS; Stephens JR; Reust R; Miller JA
AIDS Read; 2006 Jan; 16(1):47-8, 53-5; discussion 54-5. PubMed ID: 16433472
[TBL] [Abstract][Full Text] [Related]
3. Does dapsone increase mortality when given for prophylaxis of Pneumocystis carinii pneumonia?
Opravil M; Hirschel B; Lüthy R
AIDS; 1996 Aug; 10(9):1045-6. PubMed ID: 8853742
[No Abstract] [Full Text] [Related]
4. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
Urbancic KF; Pisasale D; Wight J; Trubiano JA
Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
[TBL] [Abstract][Full Text] [Related]
5. Iron overload as a mechanism for the lowered survival in AIDS patients receiving dapsone-iron protoxalate for secondary prophylaxis of Pneumocystis carinii pneumonia.
Weinberg GA
J Infect Dis; 1996 Jul; 174(1):241-2. PubMed ID: 8656006
[No Abstract] [Full Text] [Related]
6. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
Warnock AC; Rimland D
Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
[TBL] [Abstract][Full Text] [Related]
7. Atovaquone compared with dapsone to prevent Pneumocystis carinii pneumonia.
Horowitz HW; Wormser GP
N Engl J Med; 1999 May; 340(19):1512-3. PubMed ID: 10328722
[No Abstract] [Full Text] [Related]
8. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group.
El-Sadr WM; Murphy RL; Yurik TM; Luskin-Hawk R; Cheung TW; Balfour HH; Eng R; Hooton TM; Kerkering TM; Schutz M; van der Horst C; Hafner R
N Engl J Med; 1998 Dec; 339(26):1889-95. PubMed ID: 9862944
[TBL] [Abstract][Full Text] [Related]
9. Drug-resistant Pneumocystis carinii.
Meshnick SR
Lancet; 1999 Oct; 354(9187):1318-9. PubMed ID: 10533856
[No Abstract] [Full Text] [Related]
10. Successful desensitization to dapsone for Pneumocystis carinii prophylaxis in an HIV-positive patient.
Cook DE; Kossey JL
Ann Pharmacother; 1998 Dec; 32(12):1302-5. PubMed ID: 9876811
[TBL] [Abstract][Full Text] [Related]
11. Alternative dapsone dosage regimen for prophylaxis of Pneumocystis carinii pneumonia.
Gatti G; Fioredda F; Lorusso C; Cruciani M; Bassetti D
Pediatr Infect Dis J; 1996 Feb; 15(2):183-4. PubMed ID: 8822303
[No Abstract] [Full Text] [Related]
12. Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy.
East J; Blanton LS
Antimicrob Agents Chemother; 2012 Feb; 56(2):1081-3. PubMed ID: 22123706
[TBL] [Abstract][Full Text] [Related]
13. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
Girard PM; Landman R; Gaudebout C; Olivares R; Saimot AG; Jelazko P; Gaudebout C; Certain A; Boué F; Bouvet E
N Engl J Med; 1993 May; 328(21):1514-20. PubMed ID: 8479488
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials Group.
McIntosh K; Cooper E; Xu J; Mirochnick M; Lindsey J; Jacobus D; Mofenson L; Yogev R; Spector SA; Sullivan JL; Sacks H; Kovacs A; Nachman S; Sleasman J; Bonagura V; McNamara J
Pediatr Infect Dis J; 1999 May; 18(5):432-9. PubMed ID: 10353516
[TBL] [Abstract][Full Text] [Related]
15. [Effect of dapsone on survival in HIV infected patients: a meta- analysis of finished trials].
Saillourglénisson F; Chêne G; Salmi LR; Hafner R; Salamon R
Rev Epidemiol Sante Publique; 2000 Jan; 48(1):17-30. PubMed ID: 10740082
[TBL] [Abstract][Full Text] [Related]
16. Low-dose dapsone, co-trimoxazole, and survival in Pneumocystis carinii primary prophylaxis.
Antinori A; Murri R; Ammassari A
AIDS; 1996 Aug; 10(9):1046-7. PubMed ID: 8853743
[No Abstract] [Full Text] [Related]
17. Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals.
Jorde UP; Horowitz HW; Wormser GP
AIDS; 1993 Mar; 7(3):355-9. PubMed ID: 8471198
[TBL] [Abstract][Full Text] [Related]
18. Bilateral upper-lobe cavitary Pneumocystis carinii pneumonia in a patient on dapsone prophylaxis.
Jawahar DA; Dama S; Miarrostami R; Sadagdhar H; Anandarao N
Am J Med Sci; 1999 Feb; 317(2):137-9. PubMed ID: 10037118
[TBL] [Abstract][Full Text] [Related]
19. Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels.
Williams S; MacDonald P; Hoyer JD; Barr RD; Athale UH
Pediatr Blood Cancer; 2005 Jan; 44(1):55-62. PubMed ID: 15390276
[TBL] [Abstract][Full Text] [Related]
20. Dapsone/pyrimethamine versus aerosolized pentamidine as prophylaxis against PCP in HIV infection.
Dorrell L; McCallum AK; Snow MH; Ong EL
AIDS Patient Care; 1995 Oct; 9(5):224-8. PubMed ID: 11361401
[No Abstract] [Full Text] [Related]
[Next] [New Search]
